Greg Went

Greg Went has a strong background in the biotechnology and pharmaceutical industries. Greg is currently the CEO and Chairman of Reflexion Pharmaceuticals, a position they have held since 2021. Prior to that, they were the Co-Founder and Chairman of SynaVir, where they focused on developing antiviral regimens to combat global pandemics.

Before their role at SynaVir, Went founded Adamas Pharmaceuticals in 2004 and served as the CEO and Chairman until 2019. At Adamas Pharmaceuticals, their approach to treating chronic neurologic diseases involved mapping complex disease and drug activity patterns. Greg then transitioned to a strategic advisor role until 2020.

Went's experience also includes co-founding Tethys Bioscience in 2003 and serving as a board member until 2013. Greg was a board member at Parallele Biosciences (Affymetrix) from 2001 to 2005 and held the position of COO and board member at DNA Sciences from 2000 to 2001. Additionally, they co-founded CuraGen Corporation in 1991 and served as the COO and board member until 1999. At CuraGen, they led the development of their genomics platform and played a role in creating genomics-pharma partnerships.

Overall, Went's work experience demonstrates their expertise in the biotech industry, particularly in developing novel treatments and pharmaceutical partnerships.

Greg Went graduated with a Bachelor of Science degree in Chemical Engineering from Carnegie Mellon University in 1985. Greg then went on to pursue a Ph.D. in Chemical Engineering at the University of California, Berkeley, from 1985 to 1990.